

9 November 2022

Renal Cell Carcinoma and Melanoma Treatment

1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:

• Avelumab + Axitinib	7
• Axinitib	0
• Cabozantinib	15
• Everolimus	0
• Lenvatinib + Everolimus	<5
• Nivolumab	25
• Nivolumab + Cabozantinib	<5
• Nivolumab + Ipilimumab	5
• Pazopanib	<5
• Pembrolizumab + Axitinib	0
• Pembrolizumab + Lenvatinib	0
• Pembrolizumab monotherapy	0
• Radiotherapy only	12
• Sunitinib	6
• Temsirolimus	0
• Tivozanib	14
• Other active systemic anti-cancer therapy	
• Palliative care only	

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

• Cobimetinib	0
• Dabrafenib	<5
• Dabrafenib AND Trametinib	10
• Dacarbazine	0
• Encorafenib AND Binimetinib	28
• Ipilimumab	0
• ilimumab AND Nivolumab	<5
• Nivolumab	8
• Pembrolizumab	35
• Trametinib	0
• Vemurafenib	0

9 November 2022

- **Vemurafenib AND Cobimetinib** 0
- **Other active systemic anti-cancer therapy:**
 - Levatinib+Pembro <5
 - Tebentafusp MAP <5
- **Palliative care only**

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act.

3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:

- **Cobimetinib**
- **Dabrafenib**
- **Dabrafenib AND Trametinib**
- **Dacarbazine**
- **Encorafenib AND Binimetinib**
- **Ipilimumab**
- **Ipilimumab AND Nivolumab**
- **Nivolumab**
- **Pembrolizumab**
- **Trametinib**
- **Vemurafenib**
- **Vemurafenib AND Cobimetinib**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

The above information is not available on RISOH (Regional Information System Oncology & Haematology).

4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

In the last 3 months, 72 full or partial nephrectomies were completed.